Clinical Trial Update: Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

View source ↗

Summary

This ClinicalTrials.gov update reports a study evaluating regorafenib (Stivarga) in metastatic colorectal cancer patients after failure of standard therapy, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Colorectal Neoplasm | Status: COMPLETED